Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus
- PMID: 12966601
Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus
Abstract
Objective: To develop a measurement of lupus disease activity over time.
Methods: We studied patients from the University of Toronto Lupus Clinic with "regular" followup, defined as having been in the clinic for at least 3 visits and never having been away from the clinic for a period exceeding 18 consecutive months. For each visit, disease activity was evaluated with the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). The common approach to summarize over multiple visits by calculating a mean ignores the presence of varying time intervals between visits. We used the adjusted mean SLEDAI-2K (AMS), determined by the calculation of the area under the curve of SLEDAI-2K over time by adding the area of each of the blocks of visit interval and then dividing by the length of time for the whole period. The resulting AMS has the same units as the original SLEDAI-2K. A time-dependent covariate survival analysis was done to test which of AMS, SLEDAI-2K at presentation, sex, and age at diagnosis is the best predictor of mortality.
Results: A total of 575 patients with regular followup were included. Only AMS and age at diagnosis were significant predictors. Odds ratio (OR) and 95% confidence intervals (CI) for AMS: OR 1.15 (CI 1.09, 1.20), p = 0.0001; age at diagnosis: OR 1.05 (CI 1.03, 1.06), p = 0.0001.
Conclusion: AMS represents an average disease activity measure over time and is strongly associated with mortality.
Similar articles
-
Summarizing disease features over time: II. Variability measures of SLEDAI-2K.J Rheumatol. 2007 Feb;34(2):336-40. Epub 2006 Dec 15. J Rheumatol. 2007. PMID: 17183620
-
Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE.J Rheumatol. 2005 May;32(5):824-7. J Rheumatol. 2005. PMID: 15868616
-
The effect of menopause on disease activity in systemic lupus erythematosus.J Rheumatol. 2006 Nov;33(11):2192-8. Epub 2006 Sep 15. J Rheumatol. 2006. PMID: 16981295
-
Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices.Best Pract Res Clin Rheumatol. 2005 Oct;19(5):685-708. doi: 10.1016/j.berh.2005.03.010. Best Pract Res Clin Rheumatol. 2005. PMID: 16150398 Review.
-
[Systemic lupus erythematosus in children; its feature and future].Ryumachi. 2002 Jun;42(3):573-83. Ryumachi. 2002. PMID: 12166111 Review. Japanese. No abstract available.
Cited by
-
Application of machine learning in assessing disease activity in SLE.Lupus Sci Med. 2025 Apr 8;12(1):e001456. doi: 10.1136/lupus-2024-001456. Lupus Sci Med. 2025. PMID: 40204296 Free PMC article.
-
The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosus.Rheumatology (Oxford). 2025 Apr 1;64(4):1923-1929. doi: 10.1093/rheumatology/keae362. Rheumatology (Oxford). 2025. PMID: 39141489 Free PMC article.
-
Clinical associations of serum interleukin-17 in systemic lupus erythematosus.Arthritis Res Ther. 2013 Aug 23;15(4):R97. doi: 10.1186/ar4277. Arthritis Res Ther. 2013. PMID: 23968496 Free PMC article.
-
Prognostic Factors at Diagnosis Associated With Damage Accrual in Childhood-Onset Systemic Lupus Erythematosus Patients.Front Pediatr. 2022 Apr 22;10:849947. doi: 10.3389/fped.2022.849947. eCollection 2022. Front Pediatr. 2022. PMID: 35529331 Free PMC article.
-
The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis.Clin Rheumatol. 2018 Oct;37(10):2603-2610. doi: 10.1007/s10067-018-4218-8. Epub 2018 Jul 23. Clin Rheumatol. 2018. PMID: 30039267
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical